Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Bond Index Fund ETF vs Humana Inc — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.82, while Humana Inc trades at $384.79 (market cap $44.77B). The key difference: Humana Inc pays a 0.95% dividend while Vanguard Total International Bond Index Fund ETF pays none, and Humana Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | HUM | |
|---|---|---|
52-Week High | $49.91 | $409.42 |
52-Week Low | $47.57 | $163.67 |
Market Cap | — | $44.77B |
Sector | — | Health |
Enterprise Value | — | $52.12B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNDX trades at $47.835 with minimal daily movement (+0.09%), showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts of $0.11-$0.12. Market sentiment reflects ongoing concerns about Treasury yields and inflation data, with institutional activity showing mixed positioning changes among major holders.
The international bond ETF faces headwinds from rising global yields and inflation pressures, though steady dividend income provides support. Key risks include Federal Reserve policy uncertainty and Middle East geopolitical tensions affecting oil prices. Institutional interest remains active with recent position adjustments, suggesting cautious but engaged professional investor sentiment.
Humana (HUM) trades at $386.11, up 0.17% today, with a neutral technical outlook and mixed fundamentals. The stock shows strong revenue growth reaching $129.66B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent Q2 2026 earnings beat expectations with EPS of $7.61 versus $7.27 expected, while management focuses on Medicare Advantage margin expansion and cost reductions.
Outlook remains cautiously optimistic with a consensus price target of $409.93 offering 6% upside potential. Key opportunities include Medicare Advantage growth and operational efficiency gains, while risks involve margin pressure, regulatory changes in healthcare, and competitive threats. Analyst sentiment leans neutral with 57% hold ratings amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
